查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1627937

萤光导引手术系统市场机会、成长驱动因素、产业趋势分析与预测 2024 - 2032 年

Fluorescence Guided Surgery Systems Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 145 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023 年，全球萤光导引手术系统市场估值达到 1.013 亿美元，预计 2024 年至 2032 年复合年增长率为 14.1%。精准、更有效的手术。

政府致力于加强手术基础设施的措施正在推动对萤光导引手术 (FGS) 系统的巨大需求。这些倡议通常涉及对先进医疗技术、设施升级以及鼓励使用创新工具来提高手术精度和结果的投资。这笔补助支持 OnLume 开发其 FGS 系统，旨在改进该设备，以改善血管和小淋巴组织的术中可视化，最终提高手术准确性和患者效果。

市场依类型分为 VS3 Iridium 系统、SPY 系统、PDE 系统等。 2023 年，SPY 系统细分市场占据领先地位，市场占有率为 38.1%，预计将以 15% 的复合年增长率成长。 SPY 系统以其先进的成像和精确度而闻名，它使用 ICG 萤光成像来可视化血流和组织灌注，这对于提高手术准确性至关重要，使外科医生能够评估组织活力并即时做出明智的决策。

市场范围
开始年份 2023年
预测年份 2024-2032
起始值 1.013 亿美元
预测值 3.307 亿美元
复合年增长率 14.1%

从应用来看，市场分为腹腔镜/内视镜手术和开放性手术。开放手术在 2023 年占据最大份额，达到 54.2%，这主要是由于其在复杂、广泛的手术中的作用。 FGS 系统在开放式手术中特别有用，它们可以使肿瘤和邻近组织详细可视化，有助于精确去除恶性细胞并最大限度地降低残留疾病的风险。

美国在北美 FGS 市场占据主导地位，2023 年收入为 3,840 万美元。癌症的高盛行率进一步推动了对 FGS 的需求，因为外科医生优先考虑可提高挑战性手术结果的技术。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 慢性病盛行率增加
      • 癌症和心血管疾病靶向手术的增长
      • 越来越注重改善手术效果、减少手术时间
      • 旨在改善外科基础设施的政府倡议
    • 产业陷阱与挑战
      • 手术设备及耗材成本高
      • 萤光成像程序的报销范围有限
  • 成长潜力分析
  • 监管环境
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按类型，2021 - 2032

  • 主要趋势
  • 间谍系统
  • 光动态眼 (PDE) 系统
  • VS3铱系统
  • 其他类型

第 6 章：市场估计与预测：按手术分类，2021 - 2032 年

  • 主要趋势
  • 开放性手术
  • 腹腔镜/内视镜手术

第 7 章：市场估计与预测：按应用分类，2021 - 2032

  • 主要趋势
  • 癌症手术
  • 心血管手术
  • 其他应用

第 8 章：市场估计与预测：按最终用途，2021 - 2032 年

  • 主要趋势
  • 医院和诊所
  • 门诊手术中心
  • 肿瘤中心
  • 其他最终用户

第 9 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
  • 中东和非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿联酋

第 10 章：公司简介

  • B. Braun
  • Carl Zeiss
  • Danaher Corporation
  • Getinge
  • Hamamatsu Photonics
  • Intuitive Surgical
  • KARL STORZ
  • Medtronic
  • Olympus Corporation
  • OnLume
  • Shimadzu Corporation
  • Stryker Corporation
  • Samvardhana Motherson International
  • Sumitomo Mitsui Financial Group
简介目录
Product Code: 9171

The Global Fluorescence Guided Surgery Systems Market reached a valuation of USD 101.3 million in 2023 and is projected to grow at a CAGR of 14.1% from 2024 to 2032. FGS systems enhance surgical procedures by providing real-time imaging that differentiates tissues with fluorescent dyes, supporting more precise and effective surgeries.

Government initiatives focused on enhancing surgical infrastructure are driving significant demand for fluorescence-guided surgery (FGS) systems. These initiatives typically involve investments in advanced medical technologies, facility upgrades, and encouraging the use of innovative tools that improve surgical precision and outcomes. The grant supports OnLume's development of its FGS system, aiming to refine the device for improved intraoperative visualization of blood vessels and small lymphatic tissues, ultimately enhancing surgical accuracy and patient results.

The market is categorized by type into VS3 Iridium systems, SPY systems, PDE systems, and others. In 2023, the SPY system segment led with a market share of 38.1% and is expected to grow at a 15% CAGR. Known for its advanced imaging and precision, the SPY system uses ICG fluorescence imaging to visualize blood flow and tissue perfusion essential for enhancing surgical accuracy by enabling surgeons to assess tissue viability and make informed decisions in real-time.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$101.3 Million
Forecast Value$330.7 Million
CAGR14.1%

In terms of application, the market is divided into laparoscopic/endoscopic surgery and open surgery. Open surgery held the largest share in 2023 at 54.2%, largely due to its role in complex, extensive procedures. FGS systems are particularly beneficial in open surgeries, where they enable detailed visualization of tumors and adjacent tissues, facilitating precise removal of malignant cells and minimizing the risk of residual disease.

The U.S. dominated the North American FGS market, generating USD 38.4 million in revenue in 2023. As a hub for medical technology innovation, the U.S. leads in growth of FGS systems with advanced imaging and new fluorescent agents. The high prevalence of cancer further drives demand for FGS, as surgeons prioritize techniques that enhance outcomes in challenging surgeries.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of chronic diseases
      • 3.2.1.2 Growth in targeted surgeries for cancer and cardiovascular disorders
      • 3.2.1.3 Growing focus towards improving surgical outcomes and reducing operating time
      • 3.2.1.4 Government initiatives aimed at improving surgical infrastructure
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of surgical equipment and consumables
      • 3.2.2.2 Limited reimbursement coverage for fluorescence imaging procedures
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Porter's analysis
  • 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 SPY system
  • 5.3 Photo Dynamic Eye (PDE) system
  • 5.4 VS3 iridium system
  • 5.5 Other types

Chapter 6 Market Estimates and Forecast, By Surgery, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Open surgery
  • 6.3 Laparoscopic/endoscopic surgery

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Cancer surgeries
  • 7.3 Cardiovascular surgeries
  • 7.4 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals and clinics
  • 8.3 Ambulatory surgery centers
  • 8.4 Oncology centers
  • 8.5 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Italy
    • 9.3.5 Spain
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
  • 9.6 Middle East and Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 South Africa
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 B. Braun
  • 10.2 Carl Zeiss
  • 10.3 Danaher Corporation
  • 10.4 Getinge
  • 10.5 Hamamatsu Photonics
  • 10.6 Intuitive Surgical
  • 10.7 KARL STORZ
  • 10.8 Medtronic
  • 10.9 Olympus Corporation
  • 10.10 OnLume
  • 10.11 Shimadzu Corporation
  • 10.12 Stryker Corporation
  • 10.13 Samvardhana Motherson International
  • 10.14 Sumitomo Mitsui Financial Group